Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 5/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.38 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | SGK1 | O00141 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3128399 | 0.91 | ADRB3 (0.47) | ADRB3ADRA1AMAP2K4BRD4LMNA | |
| SCHEMBL3133931 | 0.90 | ADRB3 (0.47) | ADRB3ADRA1AMAP2K4BRD4LMNA | |
| SCHEMBL15946051 | 0.89 | ADRB3 (0.47) | ADRB3ADRA1AMAP2K4BRD4LMNA | |
| SCHEMBL2778772 | 0.89 | ADRB3 (0.45) | ADRB3ADRA1AMAP2K4BRD4LMNA | |
| SCHEMBL2151244 | 0.87 | ADRB3 (0.45) | ADRB3ADRA1AMAP2K4BRD4LMNA | |
| SCHEMBL15945990 | 0.86 | ADRB3 (0.49) | ADRB3ADRA1AMAP2K4BRD4LMNA | |
| SCHEMBL15946030 | 0.85 | ADRB3 (0.49) | ADRB3ADRA1AMAP2K4BRD4LMNA | |
| SCHEMBL15946064 | 0.84 | ADRB3 (0.49) | ADRB3ADRA1AMAP2K4BRD4LMNA | |
| SCHEMBL2151246 | 0.82 | ADRB3 (0.48) | ADRB3ADRA1AMAP2K4BRD4LMNA | |
| SCHEMBL2150889 | 0.81 | ADRB3 (0.49) | ADRB3ADRA1AMAP2K4BRD4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145198-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-05-26 | — | — | US | disclosed |
| US-9193669-B2 | Compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20140228443-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-8674137-B2 | Compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8674137-B2 | Compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20100113539-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113539-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113539-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, ALDH1A2 | ADRB3 763/4885ADRA1A 1866/4885MAP2K4 4864/4885 |
| US-20160145198-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, ALDH1A2 | ADRB3 763/4885ADRA1A 1866/4885MAP2K4 4864/4885 |
| US-20140228443-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, ALDH1A2 | ADRB3 763/4885ADRA1A 1866/4885MAP2K4 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.